Tempus Announces Four Abstracts Accepted For Presentation at the European Society ... - BioSpace

Tempus AI announced four abstracts accepted for ESMO Congress 2024, focusing on AI's impact on clinical trials, ctDNA monitoring, genomic profiling in lung cancer, and RAS/BRAF mutations in MSI/dMMR colorectal cancers.